TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject is scheduled to undergo laryngectomy and/or pharyngectomy procedure due to oncological indication~2. Subject is age 18 or older~3. Subject is willing and able to provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study~Exclusion Criteria:~1. Subjects currently enrolled in or planning to enroll in another clinical trial~2. Subjects with a known history of poor compliance with medical treatments~3. Subjects that are using or have used an investigational drug, device, or biologic within the 12 weeks prior to treatment~4. Subjects that have any significant medical condition(s) that, in the opinion of the Investigator, would interfere with protocol evaluation and participation~5. Subject has undergone previous pharyngeal reconstructive surgery~6. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment with Dehydrated Human Amnion Chorion Allograft (Type: None): None
- Standard of Care (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Suicide Prevention by Lithium - the Lithium Intervention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* suicide attempt within 3 months prior to the first drug administration~* occurrence of suicide attempt within the context of an affective spectrum disorder~* minimum age of 18 years~* ability to complete screening and baseline assessment~* ability to understand and provide informed consent~Exclusion Criteria:~* diagnosis of schizophrenia, borderline personality disorder, substance related disorders~* indication for long-term lithium treatment~* thyroid disease~* pregnancy and lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Lithium treatment
- 2 (Type: PLACEBO_COMPARATOR): Placebo treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Needle Diameter on Post Dural Puncture Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy~* pregnant~* spinal anesthesia at delivery (vaginal delivery or cesarean section emergency grade 2-4)~* informed consent~Exclusion Criteria:~* chronic headache~* (attempt to) epidural anesthesia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- G25 pencil point needle (Type: EXPERIMENTAL): healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 25 gauge pencil point needle
- G27 pencil point needle (Type: ACTIVE_COMPARATOR): healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 27 gauge pencil point needle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Weight Change With Controlled Ankle Movement (CAM) Walker Boot Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater or equal to 18 (male or female)~* Participants prescribed a CAM boot as standard of care from the study investigator's practice~* Participant willing to have weight measured at the clinic site at time of enrollment and final visit~* Participants willing to have blood drawn for Albumin level at beginning and end of study~* Participant is able to provide voluntary, written informed consent~* Participant, in the opinion of the clinical investigator, is able to understand the clinical investigation and is willing to perform all study procedures and follow-up visits.~* Fluent in written and spoken English~Exclusion Criteria:~* Participants less than 18 years of age~* Pregnant women~* Cognitive impairment~* Participants with vertigo or other balance issues~* Participants unable to provide informed consent~* Non-English speaking individuals~* Participants who will not be wearing a CAM boot for at least 6 weeks~* Participants unable/unwilling to perform upper body exercises and follow nutrition guidelines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nutrition and Exercise Counseling (Type: ACTIVE_COMPARATOR): CAM boot prescribed as standard of care Nutritional counseling provided Upper body exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit Patients in this arm compared with patients in control arm
- Control (Type: ACTIVE_COMPARATOR): CAM boot prescribed as standard of care No nutritional or exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Complementary Management of Chronic Neck and/or Low Back Pain With a Pain Relief Kit

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Over age 18 and report experiencing average daily musculoskeletal pain of moderate intensity (\>3/10) in the neck or low back for greater than 4 weeks.~Exclusion Criteria:~* Report any indication for medical clearance prior to engaging in moderate intensity exercise or if they have any other health limitations to engaging in moderate exercise.~* Additional exclusion criteria are the individual is unable to complete any of the data collection protocols, has previously been diagnosed with schizophrenia, dementia or is mentally incapable of providing informed consent or report a previous allergic reaction to kinesiotape or menthol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pain Relief Kit (Type: EXPERIMENTAL): Immediately following baseline data collection participants will be given the Pain Relief Kit and instructed about the contents. From this kit, a sample of Biofreeze® and TheraBand® Kinesiology Tape will be applied to the participant. The contents of the Pain Relief Kit will include four modes of non-pharmacological interventions that have been previously demonstrated to relieve musculoskeletal pain. Following Baseline data collection, participants will review the content of the Pain Relief Kit with a member of the research staff. During this review the subject will be informed about the recommended use of all the four modes of the non-pharmacological interventions included in the kit. This information will also be included in written form in the Pain Relief Kit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent atrial fibrillation (AF), AF persistence for \> 7 days but \< 1 year~* Total AF history \< 2 years~* Written informed consent of the patient~* Age ≥18 years~* Female patients are sterilised or postmenopausal or apply an adequate method for contraception (Pearl index \<1%) and have a negative pregnancy test (ß-HCG) and do not breastfeed/nurse.~Exclusion Criteria:~* Hemodynamic instability or symptoms not allowing cardioversion to be delayed for 3 weeks~* Myocardial infarction within the last 3 months~* Heart failure NYHA class III - IV~* Uncontrolled hypertension, defined as a systolic blood pressure \> 160 mm Hg and/or a diastolic blood pressure \> 95 mm Hg (anti-hypertensive treatment is allowed).~* Pre-treatment with an aldosterone antagonist or other potassium sparing diuretics~* Instable angina pectoris~* Use of Digitalis~* Use of class I or class III antiarrhythmic drugs (must be stopped at least 5 half-life before)~* Contraindication or hypersensitivity to ß-blockers~* Open heart surgery within the last 3 months~* Pregnancy~* Acute and reversible illnesses~* Acute and chronic infection~* Alcohol or drug abuse or a severe progressive extracardiac disease~* Untreated manifest and latent hyper- or hypothyroidism or \< 3 months peripheral euthyroidism (normal fT3)~* Moderate to severe renal insufficiency (Creatinine clearance less than 50 ml/min)~* Patients with liver cirrhosis (Child-Pugh class C)~* Co-administration of strong CYP3A4 inhibitors (e.g. Itraconazole, Ketoconazole, Ritonavir, Nelfinavir, Clarithromycin, Telithromycin and Nephazodon)~* Hypersensitivity against Eplerenone and/or one of the other components of the tablet (see Fachinformation)~* Serum potassium \> 5 mmol/l~* Patients unlikely to comply with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Eplerenone treatment
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newborn with cardiac anomaly requiring surgical intervention or a newborn that is in NICU for at least 24 hours for monitoring~* If newborn has congenital cardiac anomaly, cardiac repair must be performed at Mount Sinai Hospital~* If newborn has congenital cardiac anomaly, he/she must be managed pre-operatively for at least 24 hours at Mount Sinai Hospital~* If newborn has congenital cardiac anomaly, he/she must be managed post-operatively at Mount Sinai Hospital for at least 72 hours~Exclusion Criteria:~* Newborns with previously known anomalies other than cardiac~* Chromosomal abnormalities other than 22Q, that might have long-term neurodevelopmental implications~* Diagnosis of hypoxic-ischemic encephalopathy~* Metabolic disorder~* Other genetic disorders

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 2 Months
- Healthy Volunteers: f

Study Arms:
- Neonates with congenital heart disease (Type: None): The case group will consist of newborns born between 32 and 41 weeks gestation diagnosed with a congenital cardiac anomaly requiring surgical repair during their hospitalization and managed in the Mount Sinai Neonatal Intensive Care Unit. The control arm will include newborns born between 32 and 41 weeks without congenital cardiac anomalies. Both groups will undergo a neurological screening assessment and receive an AEEG to look at sleep wake cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Endoscopic Surgery and Exercise Therapy in Patients With Longstanding Achilles Tendinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of mid-portion achilles tendinopathy~* pain during at least 3 months~* decreased function (a score less than 80 on VISA-A)~Exclusion Criteria:~* Physiotherapy during previous three months~* history of major achilles trauma~* cardiovascular, respiratory, systemic, or metabolic conditions limiting exercise tolerance

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Endoscopic surgery (Type: EXPERIMENTAL): Ambulatory surgery. Postoperative rehabilitation. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
- Conservative treatment (Type: ACTIVE_COMPARATOR): Physiotherapy and exercise. First physiotherapy consultation: Information, advice, instructions. Exercise regime during 12 weeks in three phases.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Physiopathologic Study of Induced by Thoracotomy / Thoracoscopy Neuropathy Mechanism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria :~* patients undergoing lateral or posterolateral thoracotomy scheduled lung surgery, regardless of indication, or lung or pleural scheduled surgery (treatment of recurrent pneumothorax) by thoracoscopy;~* 18 to 80 years~* Informed consent to the trial~* Protected by the French health welfare~Exclusion Criteria:~* Refusal of the patient;~* Preexisting neuropathy ;~* Treatment of active substance known on neuropathic pain: gabapentin, pregabalin, amitryptyline, duloxetine, venlafaxine, tricyclic antidepressants, topical lidocaine or capsaicin;~* Emergency surgery;~* Specific clinical contexts including terminal or palliative neoplasia;~* Deficit psychiatric pathology and dementia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- neuropathic pain (Type: None): This study will be proposed to patients undergoing thoracotomy or thoracoscopy for partial or total lung resection in the service of Thoracic Surgery of Centre Jean Perrin (Prof. M. Filaire), the objective is to recruit 120 patients (for 100 evaluable patients) over a period of 18 months of inclusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Therapy in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Patients who are NOT diabetic, admitted with COPD who are likely to be prescribed corticosteroids as part of usual care with an admission glucose level (before steroids) between 6.1 and 11.1 mmol/l.~Exclusion criteria:~* Patients with diabetes mellitus~* Patients who are nil by mouth.~* Patients with severe co-morbid disease with an anticipated life expectancy of \< 6 months.~* Patients who are unable to provide informed consent.~* Age \<18 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Glulisine (Type: EXPERIMENTAL): Blood glucose monitoring and treatment of hyperglycaemia with insulin. Insulin to be with-held if pre meal blood glucose \< 4 mmol/l.
- 2 (Type: ACTIVE_COMPARATOR): Blood glucose monitoring for comparison with treatment arm (1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the MindMotionPRO for Early Post-stroke Upper-limb Rehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male/female \> 18 years old~* First ever unilateral supratentorial ischemic stroke with contralateral upper extremity weakness~* 1 to 6 weeks post-stroke~* Able to give informed consent~* Not participating any other intervention studies~* Experiencing motor difficulties in using the paretic arm, with a FMA-UE score in the range of 20 to 40 out of 66~* Stroke severity with NIHSS score between 5 (mild) and 14 (moderate) out of 42~* The participant is expected to remain available (geographically stable) for 4 months after enrolment.~Exclusion Criteria:~* Any medical condition compromising the safety or the ability to take part to the study (such as insufficient vision or hearing, inability to participate to therapy session, inability to communicate, upper limb condition not linked to stroke, uncontrolled blood pressure, uncontrolled diabetes, co-morbidity)~* Recurrent and moderate to high upper limb pain limiting delivery of rehabilitation dose~* History of more than one epileptic seizures since stroke onset or uncontrolled epileptic seizure~* Mild to severe cognitive impairment (Mini mental state exam (MMSE) score \< 24/30)~* Depression (Hospital Anxiety and Depression Scale \> 8/21)~* Moderate to severe hemispatial neglect compromising the ability to take part to the study, as determined by the Bells tests (\> 6 errors)~* Brain stem stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MindMotionPRO (Type: EXPERIMENTAL): MindMotionPRO exercises in addition to standard practice for upper limb rehabilitation
- Self-Directed Prescribed Exercises (Type: ACTIVE_COMPARATOR): Self-Directed Prescribed Exercises in addition to standard practice for upper limb rehabilitation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic rhinosinusitis and sinonasal polyposis who are candidates for functional endoscopic sinus surgery~Exclusion Criteria:~* Hypersensitivity to furosemide or sulfonamides~* pregnancy~* history of tinnitus~* history of sensorineural hearing loss~* poorly controlled diabetes~* current diuretic therapy~* known electrolyte disorder~* currently taking aminoglycosides~* BUN and creatinine levels out of the normal range~* history of renal disease~* allergy to sulfonamides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Furosemide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues